Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Molecular Characterization of Screen-Detected Lesions (MCL)

Consortium for Molecular and Cellular Characterization of Screen-Detected Lesions

A critical unmet need in the management of malignancies is the development of minimally invasive methods that predict whether a screen-detected lesion is indolent (i.e., requiring only careful monitoring) or progressive (requiring appropriate intervention).

DCB and the NCI Division of Cancer Prevention (DCP) supported the Molecular Characterization of Screen-Detected Lesions (MCL) consortium, which worked to comprehensively characterize cellular and molecular components of early lesions and identify features that distinguish indolent from aggressive/progressive lesions. Multi-disciplinary MCL teams (that were funded by RFA-CA-14-010 & RFA-CA-14-011) used enabling technologies to inform better predictions of the fate of precancers and early lesions.

MCL Highlight

Using histological, molecular, and immunological profiling approaches in a recent NPJ Breast Cancer study, Nachmanson et al. generated a breast precancer atlas showing the molecular and microenvironmental heterogeneity of ductal carcinoma in situ (DCIS).

Past Projects

InstitutionPrincipal Investigator(s)Project Title
Baylor College of MedicineChristopher AmosCoordinating Center: Molecular and Cellular Findings of Screen-Detected Lesions
Johns Hopkins UniversityKenneth Pienta,
Angelo De Marzo		Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African Ancestry
MD Anderson Cancer CenterAnirban MaitraImaging and Molecular Correlates of Progression in Cystic Neoplasms of the Pancreas
Stanford UniversityJames BrooksStanford Molecular and Cellular Characterization Laboratory
University of California, Los AngelesSteven Dubinett,
Denise Aberle,
Fenghai Duan,
Marc Lenburg		Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer
University of California, San FranciscoLaura Esserman,
Alexander Borowsky		Elucidating the Molecular and Contextual Basis for IDLE Utralow Risk Lesions and the Tumor Immune Microenvironment of High Risk In Situ and Invasive Breast Cancers
University of Vermont & State Agricultural CollegeJanet Stein,
Brian Sprague,
Donald Weaver		Vermont Breast Cancer Molecular Characterization Laboratory
Vanderbilt University Medical CenterPierre Massion,
Fabien Maldonado		Cellular, Molecular and Quantitative Imaging Analysis of Screening-Detected Lung Adenocarcinoma
  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Molecular Characterization of Screen-Detected Lesions (MCL) was originally published by the National Cancer Institute.”

Email